BioVaxys Technology Corp. Announces Debt Settlement to Optimize Financial Operations

BioVaxys Technology ( (TSE:BIOV) ) has provided an update.

BioVaxys Technology Corp. has announced a debt settlement agreement with THECCSGROUP, where it will issue 1,200,000 common shares to settle a $60,000 debt. This strategic move aims to preserve the company’s cash for working capital, reflecting a focus on financial stability and operational efficiency. The settlement is pending regulatory approvals and highlights BioVaxys’s commitment to maintaining its market position while managing its financial obligations.

More about BioVaxys Technology

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada. It focuses on developing novel immunotherapies using its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform. The company is engaged in treating cancers, infectious diseases, antigen desensitization, and other immunological fields, with a pipeline that includes treatments for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and ovarian cancer.

YTD Price Performance: -30.0%

Average Trading Volume: 312,972

Technical Sentiment Signal: Buy

Current Market Cap: $11.14M

See more insights into BIOV stock on TipRanks’ Stock Analysis page.